EGFR is frequently hyperactive in a number of cancers, including lung cancer, anal cancers and glioblastoma. Drugs such as Iressa (gefitinib) and Tarceva (erlotinib) directly target EGFR, but are only found to be effective in the absence of certain mutations that can be identified using the EGFR MASTR kit.In approximately 80% of GISTs, mutations in the cKIT gene contribute to the growth of the tumor cells. Among tumors that lack a cKIT mutation, some have mutations in a closely related gene called PDGFRA (about 5-7% of all GISTs). Knowledge of the exact type and location of a mutation in the KIT or PDGFRA gene, using the GIST MASTR kit, can be used to predict the likelihood that the tumor will respond to treatment with Gleevec (imatinib).
Multiplicom Launches Three New Mutation Detection Kits To Enable The Implementation Of Personalized Cancer Treatment
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.